Sitravatinib as a potent FLT3 inhibitor can overcome gilteritinib resistance in acute myeloid leukemia

BACKGROUND: Gilteritinib is the only drug approved as monotherapy for acute myeloid leukemia (AML) patients harboring FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutation throughout the world. However, drug resistance inevitably develops in clinical. Sitravatinib is a multi-kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yvyin, Wang, Peihong, Wang, Yang, Shen, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872318/
https://www.ncbi.nlm.nih.gov/pubmed/36691065
http://dx.doi.org/10.1186/s40364-022-00447-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872318/
https://www.ncbi.nlm.nih.gov/pubmed/36691065
http://dx.doi.org/10.1186/s40364-022-00447-4

Ejemplares similares